Cti Biopharma Stock Price, News & Analysis

CTI BioPharma Corp. (Nasdaq: CTIC) announced that VONJO™ (pacritinib) has been included in the NCCN Clinical Practice Guidelines as a recommended treatment for myelofibrosis patients. This designation, a Category 2A recommendation, applies to high-risk patients with platelet counts below 50 x 10⁹/L and provides first-line treatment options where none exist. VONJO is the only FDA-approved therapy with this designation, offering hope for patients with limited treatment options.

CTI BioPharma Corp. (NASDAQ: CTIC) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 p.m. ET. The presentation will be available via a live webcast on their website.

CTI BioPharma is focused on developing therapies for blood-related cancers, with its FDA-approved product VONJO^TM designed for myelofibrosis patients. The company is also conducting the Phase 3 PACIFICA study to further assess VONJO's efficacy.

CTI BioPharma Corp. announced the FDA approval of VONJO (pacritinib) for treating adult myelofibrosis patients with thrombocytopenia. The commercial launch is underway, backed by a $60 million payment from DRI Healthcare Trust triggered by this approval. The company reported a net loss of $36.8 million for Q4 2021, compared to $15 million in Q4 2020, and an annual net loss of $97.9 million versus $52.5 million in 2020. Cash and equivalents stood at $65.4 million at year-end, expected to fund operations through Q4 2022.

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 1:30 p.m. ET. This virtual event will be accessible via live webcast and replay on CTI's investor website. CTI focuses on developing targeted therapies for blood-related cancers, including their FDA-approved product VONJO (pacritinib), which treats myelofibrosis in patients with low platelet counts. The company is also conducting the Phase 3 PACIFICA study for VONJO.

CTI BioPharma Corp. announced FDA approval for VONJO (pacritinib), a treatment for adults with intermediate or high-risk myelofibrosis and low platelet counts (<50 × 10⁹/L). VONJO is the first therapy targeting patients with cytopenic myelofibrosis. Based on the PERSIST-2 trial, 29% of patients experienced significant spleen volume reduction. The company is financially prepared for VONJO's commercial launch, with $65 million in cash as of Dec 31, 2021. However, patients may face adverse effects like diarrhea and thrombocytopenia, and further trials are required to confirm clinical benefits.

CTI BioPharma Corp. (NASDAQ: CTIC) announced the granting of an equity inducement award to a new employee on February 16, 2022. This award, outside of the Amended and Restated 2017 Equity Incentive Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received options for 12,000 shares of common stock, vesting 25% annually over four years, contingent on continued employment. The exercise price will match the stock’s closing price on the grant date. CTI BioPharma focuses on developing targeted therapies for blood-related cancers and is headquartered in Seattle.

On January 5, 2022, CTI BioPharma Corp. (NASDAQ: CTIC) granted an equity inducement award to a new employee, with options to purchase 22,000 shares of common stock. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was crucial for the employee's acceptance of the position. The options will have an exercise price equal to the stock's closing price on the Grant Date and vest over four years, contingent upon continued employment. CTI BioPharma specializes in developing targeted therapies for blood-related cancers, notably focusing on pacritinib.

CTI BioPharma Corp. (Nasdaq: CTIC) showcased five scientific posters on pacritinib at the 63rd American Society of Hematology Annual Meeting in Atlanta from December 11-14, 2021. The data highlights pacritinib's efficacy in treating cytopenic myelofibrosis, particularly in patients with severe thrombocytopenia. Notably, full-dose pacritinib showed superior response rates compared to lower doses of ruxolitinib, with a favorable safety profile. The upcoming PDUFA action date for pacritinib is set for February 28, 2022, as CTI seeks FDA approval for this treatment option.

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview on December 6, 2021, at 3:40 p.m. ET during the JMP Securities Hematology & Oncology Summit, held virtually. The presentation will be available for live streaming and replay on the company’s website. CTI BioPharma focuses on developing targeted therapies for blood-related cancers, particularly with their candidate pacritinib, currently in late-stage development. The company is headquartered in Seattle, Washington.